The decision to expand the development plan follows recently reported promising preclinical findings demonstrating that ...
Silexion Therapeutics (SLXN) announced an expanded development plan for its next-generation siRNA candidate, SIL204. This strategy integrates ...
At close: March 28 at 4:00:01 p.m. EDT ...
Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.
Exelixis, Inc announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older with ...
As of 10:44:43 a.m. EDT. Market Open.
After hours: 24 March at 17:51:38 GMT-4 Loading Chart for CYCN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback